PE20090809A1 - Compuestos heterociclicos como agentes moduladores del receptor farnesoide x (fxr) - Google Patents
Compuestos heterociclicos como agentes moduladores del receptor farnesoide x (fxr)Info
- Publication number
- PE20090809A1 PE20090809A1 PE2008001168A PE2008001168A PE20090809A1 PE 20090809 A1 PE20090809 A1 PE 20090809A1 PE 2008001168 A PE2008001168 A PE 2008001168A PE 2008001168 A PE2008001168 A PE 2008001168A PE 20090809 A1 PE20090809 A1 PE 20090809A1
- Authority
- PE
- Peru
- Prior art keywords
- link
- fxr
- receptor
- farnesoid
- heterocyclic compounds
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 102100038495 Bile acid receptor Human genes 0.000 title 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 title 2
- -1 ISOPROPYL Chemical group 0.000 abstract 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical group ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Chemical group 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical group F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- XIPUIGPNIDKXJU-UHFFFAOYSA-N [CH]1CC1 Chemical group [CH]1CC1 XIPUIGPNIDKXJU-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94997407P | 2007-07-16 | 2007-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090809A1 true PE20090809A1 (es) | 2009-06-27 |
Family
ID=39855171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001168A PE20090809A1 (es) | 2007-07-16 | 2008-07-11 | Compuestos heterociclicos como agentes moduladores del receptor farnesoide x (fxr) |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8153624B2 (OSRAM) |
| EP (1) | EP2178851B1 (OSRAM) |
| JP (1) | JP5373788B2 (OSRAM) |
| KR (1) | KR101157334B1 (OSRAM) |
| CN (1) | CN101743232B (OSRAM) |
| AR (1) | AR067540A1 (OSRAM) |
| AT (1) | ATE539065T1 (OSRAM) |
| AU (1) | AU2008276236B2 (OSRAM) |
| BR (1) | BRPI0814571A2 (OSRAM) |
| CA (1) | CA2693406C (OSRAM) |
| CL (1) | CL2008002051A1 (OSRAM) |
| CO (1) | CO6270212A2 (OSRAM) |
| CY (1) | CY1112298T1 (OSRAM) |
| DK (1) | DK2178851T3 (OSRAM) |
| DO (1) | DOP2010000018A (OSRAM) |
| EA (1) | EA016475B1 (OSRAM) |
| EC (1) | ECSP109879A (OSRAM) |
| ES (1) | ES2376176T3 (OSRAM) |
| HR (1) | HRP20120048T1 (OSRAM) |
| IL (1) | IL202234A0 (OSRAM) |
| MA (1) | MA31683B1 (OSRAM) |
| MX (1) | MX2010000502A (OSRAM) |
| PE (1) | PE20090809A1 (OSRAM) |
| PL (1) | PL2178851T3 (OSRAM) |
| PT (1) | PT2178851E (OSRAM) |
| RS (1) | RS52216B (OSRAM) |
| SI (1) | SI2178851T1 (OSRAM) |
| SV (1) | SV2010003458A (OSRAM) |
| TN (1) | TN2010000028A1 (OSRAM) |
| TW (1) | TW200906823A (OSRAM) |
| WO (1) | WO2009012125A1 (OSRAM) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012087521A1 (en) * | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| JP2014500318A (ja) * | 2010-12-20 | 2014-01-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ファルネソイドｘ受容体を調節するための組成物および方法 |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| PT3043865T (pt) | 2013-09-11 | 2021-01-14 | Univ Claude Bernard Lyon | Métodos e composições farmacêuticas para o tratamento da infeção por vírus da hepatite b |
| CU24375B1 (es) | 2013-11-05 | 2018-12-05 | Novartis Ag | Derivados de pirazol fusionados activos como moduladores del receptor de farnesoide x |
| CN104045635A (zh) * | 2014-06-23 | 2014-09-17 | 华东理工大学 | 3,4,5-三取代异恶唑类化合物及其用途 |
| EP3006939A1 (en) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| EP3034501A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| EA036404B1 (ru) | 2015-02-06 | 2020-11-06 | Интерсепт Фармасьютикалз, Инк. | Фармацевтические композиции для комбинированной терапии |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| WO2016161003A1 (en) | 2015-03-31 | 2016-10-06 | Enanta Phamraceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| EA036757B1 (ru) | 2015-04-07 | 2020-12-17 | Интерсепт Фармасьютикалз, Инк. | Фармацевтические композиции для комбинированной терапии |
| CN106946867B (zh) * | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
| CN107021958A (zh) * | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
| EP3437659B1 (en) | 2016-03-28 | 2023-03-01 | Intercept Pharmaceuticals, Inc. | Combination of a fxr agonist and an angiotensin ii receptor blocker |
| US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189652A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201150A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017218337A1 (en) | 2016-06-13 | 2017-12-21 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| MA46052A (fr) | 2016-08-23 | 2021-03-17 | Ardelyx Inc | Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques |
| US11091482B2 (en) | 2016-08-23 | 2021-08-17 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
| RU2019110779A (ru) * | 2016-09-14 | 2020-10-15 | Новартис Аг | Новые схемы введения агонистов fxr |
| AU2017338853A1 (en) | 2016-10-04 | 2019-04-18 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| CN108218852A (zh) * | 2016-12-15 | 2018-06-29 | 宁波百纳西药业有限公司 | 一种螺环化合物、其制备方法、组合物及用途 |
| SI3600309T1 (sl) | 2017-03-28 | 2022-10-28 | Gilead Sciences, Inc. | Terapevtske kombinacije za zdravljenje bolezni jeter |
| JP2020515564A (ja) | 2017-03-30 | 2020-05-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物 |
| JP6886074B2 (ja) * | 2017-04-12 | 2021-06-16 | イルドン ファーマシューティカル カンパニー リミテッド | 核受容体の効能剤であるイソオキサゾール誘導体及びその用途 |
| CN109265471B (zh) * | 2017-06-30 | 2021-06-04 | 轩竹生物科技有限公司 | Fxr受体激动剂 |
| CN109320509B (zh) * | 2017-07-31 | 2022-02-08 | 轩竹生物科技股份有限公司 | Fxr受体激动剂 |
| MA50242A (fr) | 2017-09-14 | 2020-07-22 | Ardelyx Inc | Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques mutagènes et fibrotiques |
| CN111278817B (zh) | 2017-11-01 | 2023-05-16 | 百时美施贵宝公司 | 作为法尼醇x受体调节剂的多环化合物 |
| AR113820A1 (es) | 2017-11-01 | 2020-06-17 | Bristol Myers Squibb Co | Compuestos bicíclicos en puente como moduladores del receptor farnesoide x |
| ES2963652T3 (es) | 2017-11-01 | 2024-04-01 | Bristol Myers Squibb Co | Compuestos espirocíclicos de alquenos como moduladores del receptor x farnesoide |
| WO2019089670A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Alkene compounds as farnesoid x receptor modulators |
| JP7228595B2 (ja) | 2017-11-01 | 2023-02-24 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレーターとしてのスピロ環化合物 |
| US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| CN111263759B (zh) | 2017-12-22 | 2023-03-28 | 四川科伦博泰生物医药股份有限公司 | 异噁唑衍生物及其制备方法和用途 |
| CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| US10829486B2 (en) | 2018-02-14 | 2020-11-10 | Enanta Pharmacueticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| CN110452235B (zh) * | 2018-05-08 | 2023-02-17 | 中国科学院上海药物研究所 | 一类含氟异噁唑类化合物及其制备方法、药物组合物和用途 |
| MX2021002305A (es) * | 2018-08-30 | 2021-05-31 | Terns Pharmaceuticals Inc | Tratamiento de trastornos del higado. |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| WO2020150136A1 (en) | 2019-01-15 | 2020-07-23 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| WO2020163689A1 (en) | 2019-02-08 | 2020-08-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | 20-hete formation inhibitors |
| EA202192275A1 (ru) | 2019-02-15 | 2021-11-03 | Бристол-Маерс Сквибб Компани | Замещенные амидные соединения, полезные в качестве модуляторов фарнезоидного x-рецептора |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| CN113677666A (zh) | 2019-02-15 | 2021-11-19 | 百时美施贵宝公司 | 作为类法尼醇x受体调节剂的经取代的双环化合物 |
| AU2020221371A1 (en) | 2019-02-15 | 2021-10-07 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid x receptor modulators |
| US11524005B2 (en) | 2019-02-19 | 2022-12-13 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
| IL287159B1 (en) | 2019-04-19 | 2025-10-01 | Shanghai Inst Materia Medica Cas | Small molecules agonists for FXR (farnesoid X receptor) and method for their preparation and use |
| US11555032B2 (en) | 2019-05-13 | 2023-01-17 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| CA3142358A1 (en) | 2019-05-30 | 2020-12-03 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
| CA3139291A1 (en) | 2019-07-18 | 2021-01-21 | Jacky Vonderscher | Method for decreasing adverse-effects of interferon |
| EP4028008A4 (en) | 2019-09-12 | 2023-09-13 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| EP4054567A4 (en) * | 2019-11-08 | 2024-01-10 | Terns Pharmaceuticals, Inc. | TREATMENT OF LIVER DISEASES |
| WO2021108974A1 (en) | 2019-12-03 | 2021-06-10 | Gannex Pharma Co., Ltd | Compounds for modulating activity of fxr and uses thereof |
| ES3014367T3 (en) | 2020-01-15 | 2025-04-22 | Inst Nat Sante Rech Med | Use of fxr agonists for treating an infection by hepatitis d virus |
| KR20230024277A (ko) * | 2020-05-13 | 2023-02-20 | 테른스 파마슈티칼스, 인크. | 간 장애의 조합 치료 |
| IL300853A (en) | 2020-08-25 | 2023-04-01 | Lilly Co Eli | Polymorphs of an ssao inhibitor |
| US20220098184A1 (en) * | 2020-09-11 | 2022-03-31 | Terms Pharmaceuticals, Inc. | Solid dispersion formulations of an fxr agonist |
| WO2022082197A1 (en) * | 2020-10-15 | 2022-04-21 | Eli Lilly And Company | Polymorphs of an fxr agonist |
| CA3204800A1 (en) | 2021-01-14 | 2022-07-21 | Raphael Darteil | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| JP2024517181A (ja) | 2021-04-28 | 2024-04-19 | ウエヌイグレックオ・ファーマ | 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強 |
| EP4429665A1 (en) | 2021-11-11 | 2024-09-18 | Terns Pharmaceuticals, Inc. | Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders |
| WO2023220404A1 (en) * | 2022-05-13 | 2023-11-16 | Terns Pharmaceuticals, Inc. | Treatment of non-alcoholic steatohepatitis |
| CN115850152B (zh) * | 2022-12-20 | 2025-10-31 | 河北鼎泰制药有限公司 | 一种杂质A-7-imp3的制备方法及其用途 |
| KR20250166323A (ko) | 2023-04-07 | 2025-11-27 | 테른스 파마슈티칼스, 인크. | 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07138258A (ja) | 1993-11-16 | 1995-05-30 | Taiho Yakuhin Kogyo Kk | チアゾリジンジオン誘導体又はその塩 |
| AU2389100A (en) | 1998-12-23 | 2000-07-12 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
| US7105556B2 (en) | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| US6967212B2 (en) * | 2001-05-30 | 2005-11-22 | Bristol-Myers Squibb Company | Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| DE60131967D1 (de) | 2001-08-13 | 2008-01-31 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| AU2003248861B2 (en) | 2002-07-09 | 2009-01-22 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| AU2003290700A1 (en) * | 2002-11-22 | 2004-06-18 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| US7863302B2 (en) | 2006-02-03 | 2011-01-04 | Eli Lilly And Company | Compounds and methods for modulating FX-receptors |
| AR061101A1 (es) | 2006-05-24 | 2008-08-06 | Lilly Co Eli | Compuesto de fenil-triazolil- metoxi- arilo, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende |
| CN101448791B (zh) * | 2006-05-24 | 2011-11-16 | 伊莱利利公司 | Fxr激动剂 |
-
2008
- 2008-07-03 TW TW097125064A patent/TW200906823A/zh unknown
- 2008-07-11 DK DK08781651.8T patent/DK2178851T3/da active
- 2008-07-11 HR HR20120048T patent/HRP20120048T1/hr unknown
- 2008-07-11 AT AT08781651T patent/ATE539065T1/de active
- 2008-07-11 EP EP08781651A patent/EP2178851B1/en active Active
- 2008-07-11 RS RS20120099A patent/RS52216B/sr unknown
- 2008-07-11 PL PL08781651T patent/PL2178851T3/pl unknown
- 2008-07-11 MX MX2010000502A patent/MX2010000502A/es active IP Right Grant
- 2008-07-11 EA EA201070148A patent/EA016475B1/ru not_active IP Right Cessation
- 2008-07-11 SI SI200830514T patent/SI2178851T1/sl unknown
- 2008-07-11 WO PCT/US2008/069719 patent/WO2009012125A1/en not_active Ceased
- 2008-07-11 ES ES08781651T patent/ES2376176T3/es active Active
- 2008-07-11 AU AU2008276236A patent/AU2008276236B2/en not_active Ceased
- 2008-07-11 CN CN2008800247651A patent/CN101743232B/zh active Active
- 2008-07-11 PE PE2008001168A patent/PE20090809A1/es not_active Application Discontinuation
- 2008-07-11 KR KR1020107000896A patent/KR101157334B1/ko not_active Expired - Fee Related
- 2008-07-11 JP JP2010517082A patent/JP5373788B2/ja active Active
- 2008-07-11 US US12/600,879 patent/US8153624B2/en active Active
- 2008-07-11 PT PT08781651T patent/PT2178851E/pt unknown
- 2008-07-11 CA CA2693406A patent/CA2693406C/en not_active Expired - Fee Related
- 2008-07-11 BR BRPI0814571-7A2A patent/BRPI0814571A2/pt not_active IP Right Cessation
- 2008-07-14 AR ARP080103026A patent/AR067540A1/es not_active Application Discontinuation
- 2008-07-14 CL CL2008002051A patent/CL2008002051A1/es unknown
-
2009
- 2009-11-19 IL IL202234A patent/IL202234A0/en unknown
-
2010
- 2010-01-12 CO CO10002335A patent/CO6270212A2/es not_active Application Discontinuation
- 2010-01-12 DO DO2010000018A patent/DOP2010000018A/es unknown
- 2010-01-15 SV SV2010003458A patent/SV2010003458A/es not_active Application Discontinuation
- 2010-01-15 EC EC2010009879A patent/ECSP109879A/es unknown
- 2010-01-15 TN TNP2010000028A patent/TN2010000028A1/fr unknown
- 2010-02-11 MA MA32615A patent/MA31683B1/fr unknown
-
2012
- 2012-01-27 CY CY20121100098T patent/CY1112298T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090809A1 (es) | Compuestos heterociclicos como agentes moduladores del receptor farnesoide x (fxr) | |
| ES2477940T3 (es) | Imidazoles condensados y composiciones que los incluyen para el tratamiento de enfermedades parasitarias tales como por ejemplo malaria | |
| NI200900031A (es) | Compuestos de n-metilaminometil isoindol y composiciones que los comprenden y métodos para usar los mismos. | |
| AR062111A1 (es) | Derivados de beta-d-glucopiranosil indol, metodo de preparacion, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos. | |
| ECSP077848A (es) | Compuestos espiroheterocíclicos y sus usos como agentes terapéuticos | |
| SV2016005192A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| AR092284A1 (es) | MODULADORES SELECTIVOS DE RECEPTORES DE ANDROGENOS (SARMs) Y USOS DE LOS MISMOS | |
| PE20080997A1 (es) | Compuestos n-fenilmetil-5-oxo-prolina-2-amida como moduladores de receptores p2x7 | |
| NI200800290A (es) | Moduladores bencimidazólicos de vr1 | |
| MX2020004405A (es) | Compuestos biciclicos en puente como moduladores del receptor farnesoide x. | |
| AR071385A1 (es) | Compuestos de 2-imino-3-metil pirrolopirimidinona sustituida con tiofenilo,composiciones farmaceuticas que los contienen,y uso de los mismos para el tratamiento de patologias asociadas con la proteina beta amiloide,tales como alzheimer y otros formas de demencia. | |
| NI200900170A (es) | Derivados de isoindolina 4' - o - sustituidos y composiciones que los comprenden y métodos para usar los mismos. | |
| CR20130307A (es) | Composiciones y métodos para modular el fxr | |
| EA200702497A1 (ru) | Замещенные арилпиразолы для применения против паразитов | |
| CO6190511A2 (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| PE20060610A1 (es) | Derivados tetraciclicos como moduladores de los receptores de estrogeno | |
| MA40281B1 (fr) | Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t | |
| EA201171488A1 (ru) | Lxr модуляторы | |
| HRP20100194T8 (hr) | Perikondenzirani triciklički spojevi, korisni kao antibakterijska sredstva | |
| PE20180252A1 (es) | Moduladores alostericos positivos del receptor muscarinico m2 | |
| CO2019002618A2 (es) | Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos | |
| AR079467A1 (es) | Derivados heterociclicos nitrogenados de etinilo, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para tratar y/o prevenir enfermedades cognitivas o esquizofrenia. | |
| CO2023001848A2 (es) | Compuestos de indol como moduladores de los receptores de andrógenos | |
| CL2020003197A1 (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos. | |
| CR20110302A (es) | ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |